RxDoctor Payments Data

Joshua Black, APRN

Psychiatric/Mental Health · Willow Street, PANPI 1669024246

Payments from drug & device makers

$2,428in general payments, 2019–2025

Across 49 payments — averaging $49.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$552
  • Neurocrine Biosciences, Inc.$415
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$350
  • Acadia Pharmaceuticals Inc$311
  • Alkermes, Inc.$236
  • Avanir Pharmaceuticals, Inc.$208
  • plus $356 from 5 others

What the payments were for

  • Speaking & faculty fees$35014%
  • Food & beverage$1,74372%
  • Education$33614%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,428 in reported general payments places this provider in the 80th percentile of 1,041 psychiatric/mental health providers in Pennsylvania.

See all psychiatric/mental health providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$205,423
Medicare patients
579
Services billed
2,440

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate63$389,101
Invega SustennaPaliperidone Palmitate70$239,991
VraylarCariprazine Hcl172$203,287
Austedo XrDeutetrabenazine23$83,181
Paliperidone ErPaliperidone187$57,721
Chlorpromazine Hcl103$48,517
NuplazidPimavanserin Tartrate12$31,922
Clozapine343$29,634
Divalproex Sodium589$22,785
Olanzapine722$21,579
Aripiprazole418$21,448
TrintellixVortioxetine Hydrobromide72$21,186
Quetiapine Fumarate613$18,341
Lorazepam945$13,150
Sertraline Hcl1,026$12,461

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$415$389,10163 claims
Johnson & JohnsonInvega Sustenna$12$239,99170 claims
AbbVieVraylar$159$203,287172 claims
Teva Pharmaceuticals USA, Inc.Austedo Xr$552$83,18123 claims
Acadia Pharmaceuticals IncNuplazid$311$31,92212 claims
Avanir Pharmaceuticals, Inc.Nuedexta$208$11,06415 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,041 psychiatric/mental health providers in Pennsylvania.

Other psychiatric/mental health in Willow Street

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →